The role of a patient's serostatus against CMV on the final outcome has to be yet specifically addressed in the setting of haploidentical hematopoietic stem cell transplantation using posttransplant high-dose cyclophosphamide (haplo-HSCT with PT-Cy). The issue is noteworthy since the reproducibility, the acceptable toxicity and the ease of finding a donor within the appropriate timing is conducting to an increasing use of haplo-HSCT with PT-Cy overall, 1 even challenging the use of matched unrelated donors in particular situations. 2, 3 CMV infection is known to be responsible for substantial morbidity and mortality following allogeneic transplantation; 4, 5 most findings suggest that CMV serostatus significantly affects patient survival especially in situations of sustained immunosuppression (myeloablative conditioning, unrelated donor, use of T-cell depletion), whereas the same question is still open in the setting of haplo-HSCT with PT-Cy.
We here conducted a cohort study on a series of 207 consecutive adult patients receiving haplo-HSCT with PT-Cy for a hematological disease at two institutions (Institut Paoli-Calmettes, Marseille, France and Humanitas Clinical and Research Center, Rozzano, Italy) from September 2009 to April 2015. Data were collected as of 9th July 2015. Patients were grouped into four cohorts according to patient/donor CMV serostatus and followed up to the last contact. Administration of conditioning regimens and the choice of bone marrow (BM) or peripheral blood stem cells (PBSC) source followed internal policies, as previously reported; 2, 6, 7 the choice of the haploidentical donor was based on general criteria that are also valid for HLA-identical sibling or unrelated donor selection with the only additional requirement of the absence of donor-specific antibodies. Whenever possible, a CMV-matched donor was chosen (particularly for CMV − patients).
Main patients', donors' and transplant characteristics are shown in Table 1 . The first cohort (patient/donor CMV − / − pairs) was the reference group. The baseline transplant characteristics did not significantly differ among the groups except for the source of stem cells that was unbalanced in cohort 1 (ratio PBSC:BM = 3:1) versus the cohorts 2, 3 and 4 (approx. ratio 1:1, P = 0.04), a higher proportion of male donors in the cohorts 3 and 4 (P = 0.05) and a lower age of donors who are CMV negative (P = 0.01). Two-year overall survival (OS) was 62% (95% confidence interval (CI): 41-83), 65% (95% CI: 45-85), 50% (95% CI: 40-60), 42% (95% CI: 24-60) in cohorts 1 to 4, respectively (P = 0.10 for heterogeneity; Figure 1a ). No significant difference was observed when comparing survival of cohort 1 versus 2 (P = 0.98) and cohort 3 versus 4 (P = 0.66), thus we grouped cohorts 1 with 2 (all CMV − patients) and 3 with 4 (all CMV+ patients), finding a 2-year OS of 64% (95% CI: 49-79) and 48% (95% CI: 39-57), respectively (P = 0.01). After adjustment for the other significant variables in univariate Cox regression analysis, we observed an increased mortality risk for recipient/donor CMV+/+ pairs (hazard ratio (HR):
2.28 (95% CI: 1.16-4.47, P = 0.02)) and for CMV+/ − ones (HR: 2.18 (95% CI: 1.01-4.69, P = 0.05)) compared with CMV − / − pairs (cohort 1). Similarly, no difference was observed after adjustment when comparing cohort 1 with 2 (P = 0.96) and cohort 3 with 4 (P = 0.85). Two-year non-relapse mortality (NRM) was 9% (95% CI: 0-18), 17% (95% CI: 1-32), 24% (95% CI: 16-33) and 31% (95% CI: 14-47) in cohorts 1 to 4, respectively (P = 0.11 for heterogeneity; Figure 1b ). After adjustment, the NRM risk was significantly higher for recipient/donor CMV+/+ pairs (HR: 3.64 (95% CI: 1.09-12.20, P = 0.04)) and for CMV+/ − ones (HR: 3.80 (95% CI: 1.02-14.09, P = 0.05)) compared with CMV − / − pairs. Again, no significant difference was observed in the comparison of cohort 1 with 2 (P = 0.68) and of cohort 3 with 4 (P = 0.90). Causes of NRM were: infection by unknown pathogen(s) (n = 14), bacterial infection (n = 6), viral infection (n = 6), acute GvHD (n = 3), secondary malignancy (n = 3), multiorgan failure (n = 3), heart failure (n = 2), graft failure (n = 2), invasive aspergillosis (n = 2), liver failure (n = 1), thrombotic microangiopathy (n = 1), neurological complication (n = 1) and hemolytic anemia (n = 1).
Grade 2-4 acute GvHD occurred in 11, 7, 30 and 9 patients in cohorts 1 to 4, with rates of 30%, 27%, 27% and 26% respectively (P = 0.86). Grade 3-4 acute GvHD occurred in 1, 2, 7 and 2 patients in cohorts 1 to 4, with a rate of 3%, 8%, 6% and 6%, respectively (P = 0.86). Chronic GvHD occurred in 4, 5, 12 and 4 patients in cohorts 1 to 4, with rates of 11%, 19%, 11% and 11%, respectively (P = 0.12). We observed a total of 56 events of relapse or progression (applicable to patients in CR or with measurable disease before haplo-HSCT respectively) at a median of 209 days after transplantation (range: 10-416). Analyzed separately, 11, 5, 29 and 11 events occurred in cohorts 1 to 4, with rates of 30%, 19%, 26% and 31% without significant differences among the groups (P = 0.71).
The cumulative incidence of CMV reactivation was 42% (95% CI: 35-49) for the entire population, with the first event occurring at day +10 and the last one at day +421 after transplantation. When analyzed separately, we found 0%, 45% (95% CI: 24-65), 52% (95% CI: 43-62), 51% (95% CI: 34-68) cumulative incidence in cohorts 1 to 4, respectively, with a longer median time to first reactivation in the cohort 2 versus 3 and 4: day +63 (range: 33-275) versus day +41 (range: 10-421) and day +42 (range: 10-71). Two non-fatal (one colitis, one pneumonia) and one fatal (pneumonia) CMV diseases occurred, this latter in cohort 3.
In the present analysis conducted on 207 consecutive adult patients receiving haplo-HSCT with PT-Cy for a hematological malignancy, we found higher NRM and worse survival among CMV + patients compared with CMV − ones. Although the low number of patients in each cohort prevents any further conclusion, the outcome seems to be unaffected (or little) by the donor CMV serological status, although only a registry-based or a collaborative study with larger cohorts of patients may provide additional information in this sense.
Being the first report addressing such an issue in this specific setting, the present analysis also includes information on the incidence and timing of CMV reactivation, thus providing useful information for the management of such a potentially lifethreatening transplant complication. Despite being indirect, the data may suggest a better immune reconstitution after PT-Cy than after anti-thymocyte globulin (ATG), 8, 9 infections (in particular of viral origin) occur frequently in the early post-transplant period after PT-Cy; 10 this may explain our findings of higher NRM and worse survival among CMV+ patients, events that are possibly related to the high cumulative incidence of CMV infectious episodes observed here in the cohorts 3 and 4. In addition, unfortunately the treatment with the available anti-CMV agents may be complicated by myelotoxicity and/or renal impairment, therefore this may conduct ultimately to fatal complications, even if the final event is different from the CMV infection itself.
The present results are consistent with reports from other transplant settings, in particular when ATG is administered as GvHD prophylaxis and when the donor is CMV seronegative; [11] [12] [13] similarly, the profound state of immune suppression here prevents or impairs the prompt recovery of anti-CMV immunity, this latter recently associated with a better protection from overall infections in the context of haplo-HSCT with PT-Cy. Abbreviations: BM = bone marrow; HCT-CI = hematopoietic cell transplantation-specific comorbidity index; MAC = myeloablative conditioning; MDS = myelodisplastic syndrome; MPS = myeloproliferative syndrome; NMA = nonmyeloablative; RIC = reduced-intensity conditioning.
a Grouped as follows: parents versus siblings versus offspring (cousins excluded due to few numbers). The patient with diagnosis of drepanocytosis is not evaluable for DRI. NMA/RIC conditioning regimens were: Baltimore protocol as described by Luznik et al.,
1 n = 132; associations of thiotepa, fludarabine and busulfan, n = 16; association of thiotepa, fludarabine and cyclophosphamide, n = 16; association of fludarabine, busulfan and ciclophsphamide, n = 6; association of fludarabine and busulfan preceeded by debulking chemotherapy by clofarabine and cytarabine, n = 6; association of thiotepa and busulfan, n = 5. MAC were: associations of thiotepa, fludarabine and busulfan, n = 25; association of fludarabine and busulfan preceeded by debulking chemotherapy by clofarabine and cytarabine, n = 1. Bold values represent P-values less or equal to 0.05.
We cannot exclude that some effect from other variables was not found due to the limited number of patients, potentially reducing the power of analyses; this may also concern the potential role of donor CMV serological status on outcome, that could not be informative here for the same reason. Another limitation of the study is the heterogeneity of the conditioning regimens used, related to the multiple diseases treated and the distinct patient's ages and comorbidities; this might be a confounding factor since the intensity of conditioning plays a role in the immune recovery after transplant. To limit this potential bias we performed an interaction test between the recipient/ donor CMV mismatch and the conditioning intensity and we found no interaction (P = 0.25).
In conclusion, higher NRM and worse survival were observed among CMV+ patients versus CMV − ones in this large series of haplo-HSCTs with PT-Cy. The role of the donor CMV serological status in this setting deserves further investigation using larger cohorts of patients, possibly through collaborative and/or registry analysis. 
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